This result suggests that co-targeting EGFR and CXCR7 may provide new ideas for the treatment of EGFR-TKI-resistant NSCLC patients by promoting mesenchymal transformation to epithelial cells. This evidence concerns the gene EGFR and non-small cell lung carcinoma.